Perspectives in adjuvant therapy of gastric cancer.
Oncology
; 77 Suppl 1: 38-42, 2009.
Article
em En
| MEDLINE
| ID: mdl-20130430
ABSTRACT
Although the incidence of gastric cancer has been declining in Western countries, it is still a major health problem and a leading cause of cancer mortality. Surgery is the mainstay of treatment for gastric adenocarcinoma. However, even among patients undergoing gastrectomy with curative intent, 5-year survival rates are disappointing due to locoregional relapse and distant metastases. This emphasizes the importance of multidisciplinary management of patients with gastric cancer. In contrast to the preoperative approach, several phase III trials have been carried out in the adjuvant setting, but postoperative chemotherapy has not proven to be superior to surgery alone. Therefore, at present the routine use of adjuvant therapy should be regarded as an investigational approach. Improved clinical trial designs with standardized surgical techniques and the incorporation of newer active drugs are needed.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Gástricas
/
Adenocarcinoma
/
Quimioterapia Adjuvante
/
Radioterapia Adjuvante
/
Receptores ErbB
/
Gastrectomia
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Oncology
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
Itália